Fatih Şendağ

Surprised Pregnancy in First Ovulation After Laparoscopic Tubal Reanastomosis: A Case Report

234 lthough miscellaneous contraceptive options are available to provide reversible contraception, either in developed or developing countries tubal sterilization is one of the most common method used by married women.1 Most women who choose voluntary tubal sterilization as a permanent contraceptive method, will remain happy with their choice. However, owing to different reasons, such as a change of spouse, loss of children and loss of spouse, between 2 and 10% of patients who have had tubal sterilization will motivate new pregnancies by using tubal reanastomosis procedure.2 Either surgical approach or In Vitro FertilizationEmbryo Transfer (IVF-ET) can be offered as alternative treatment to these Surprised Pregnancy in First Ovulation After Laparoscopic Tubal Reanastomosis: Case Report

ADJUVAN TAMOKSİFEN TEDAVİSİ ALAN MEME KANSERLİ HASTALARDA ENDOMETRİAL NEOPLAZİ : NON-ENDOMETRİOİD ALT GRUPLARININ SUNUMU

The aim of the present study is to report the clinicopathologic features of endometrial cancers subsequently develepod after adjuvant treatment of breast cancer with tamoxifen. Seven endometrial cancers in tamoxifen-treated breast cancer patients were treated at our institution between 1994 and 2002. Medical reports of the patients were evaluated retrospectively. All patients were postmenopausal and one patient was nulliparous. The age at discovery of the endometrial carcinoma ranged from 53-78. The menopausal age ranged from 40-53. Six of seven postmenopausal patients had postmenopausal uterine bleeding as the initial complaint. Only one patient was found to have endometrial cancer at annual gynecologic examination. Endometrial neoplasia was diagnosed by dilatation and curettage in all cases. The patients had been treated with 20 mg of tamoxifen daily for 1-14 years. Six patients were found to have endometrial carcinoma during adjuvant tamoxifen treatment. Only one patient developed endometrial carcinoma six years after the cessation of adjuvant tamoxifen treatment. Histopathologic examination of the specimens revelaed five cases of adenocarcinoma and two cases of sarcoma. Malignant mixed mesodermal tumor and adenosarcoma of the endometrium developed in long-term tamoxifen users (8 and 14 years, respectively). Patients with breast cancer using adjuvant tamoxifen treatment, especially the long-term users should be monitored for the possibility of endometrial neoplasia. It is notable that five out of seven endometrial malignancies were not of endometrioid subtype.